Integral Diagnostics - Public Comps and Valuation Multiples

Integral Diagnostics Overview

About Integral Diagnostics

Integral Diagnostics is Australia’s fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.

Founded

2008

HQ

Employees

3.0K+

Website

integraldiagnostics.com.au

Sectors

Hospitals & Clinics
Medical Imaging & Diagnostics
Laboratory Services
HealthTech

Financials

LTM Revenue $444M

LTM EBITDA $88.3M

EV

$974M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Integral Diagnostics Financials

As of September 2025, Integral Diagnostics reported last 12-month revenue of $444M and EBITDA of $88.3M.

In the same period, Integral Diagnostics generated $431M in LTM gross profit and $23.9M in net income.

See Integral Diagnostics valuation multiples based on analyst estimates

Integral Diagnostics P&L

In the most recent fiscal year, Integral Diagnostics reported revenue of $408M and EBITDA of $57.0M.

Integral Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Integral Diagnostics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$444M	XXX	$408M	XXX	XXX	XXX
Gross Profit	$431M	XXX	$389M	XXX	XXX	XXX
Gross Margin	97%	XXX	96%	XXX	XXX	XXX
EBITDA	$88.3M	XXX	$57.0M	XXX	XXX	XXX
EBITDA Margin	20%	XXX	14%	XXX	XXX	XXX
EBIT	$48.7M	XXX	$37.4M	XXX	XXX	XXX
EBIT Margin	11%	XXX	9%	XXX	XXX	XXX
Net Profit	$23.9M	XXX	$3.0M	XXX	XXX	XXX
Net Margin	5%	XXX	1%	XXX	XXX	XXX
Net Debt	XXX	XXX	$188M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Integral Diagnostics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $444M. EBITDA for the last twelve months was $88.3M. In the most recent fiscal year, Integral Diagnostics achieved $408M in revenue and $57.0M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$444M	Analyst estimates available to subscribers	$408M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$431M	Analyst estimates available to subscribers	$389M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	97.1% gross margin	Analyst estimates available to subscribers	95.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$88.3M	Analyst estimates available to subscribers	$57.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	19.9% EBITDA margin	Analyst estimates available to subscribers	14.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$48.7M	Analyst estimates available to subscribers	$37.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	11.0% EBIT margin	Analyst estimates available to subscribers	9.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$23.9M	Analyst estimates available to subscribers	$3.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	5.4% net profit margin	Analyst estimates available to subscribers	0.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$188M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Integral Diagnostics

This financial data table provides comprehensive performance metrics for Integral Diagnostics, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Integral Diagnostics generated $444M in revenue over the last twelve months.
The company achieved $88.3M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $431M.
Net income over the last twelve months reached $23.9M.

Fiscal Year Performance

In the most recent fiscal year, Integral Diagnostics reported $408M in total revenue.
Fiscal year EBITDA was $57.0M.
The company maintained a gross profit margin of 95.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 14.0%.
Net profit margin reached 0.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Integral Diagnostics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Integral Diagnostics Stock Performance

Integral Diagnostics has current market cap of AUD 966M (or $628M), and EV of AUD 1.5B (or $974M).

Market Cap Evolution

Integral Diagnostics Stock Data

As of October 24, 2025, Integral Diagnostics's stock price is AUD 3 (or $2).

See Integral Diagnostics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$974M	$628M	XXX	XXX	XXX	XXX	$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Integral Diagnostics Valuation Multiples

Integral Diagnostics's trades at 2.7x EV/Revenue multiple, and 31.7x EV/EBITDA.

See valuation multiples for Integral Diagnostics and 15K+ public comps

Integral Diagnostics Financial Valuation Multiples

As of October 24, 2025, Integral Diagnostics has market cap of $628M and EV of $974M.

Equity research analysts estimate Integral Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Integral Diagnostics has a P/E ratio of 26.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$628M	XXX	$628M	XXX	XXX	XXX
EV (current)	$974M	XXX	$974M	XXX	XXX	XXX
EV/Revenue	2.2x	XXX	2.7x	XXX	XXX	XXX
EV/EBITDA	11.0x	XXX	31.7x	XXX	XXX	XXX
EV/EBIT	20.0x	XXX	30.1x	XXX	XXX	XXX
EV/Gross Profit	2.3x	XXX	n/a	XXX	XXX	XXX
P/E	26.3x	XXX	-34.5x	XXX	XXX	XXX
EV/FCF	47.5x	XXX	53.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Integral Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Integral Diagnostics Margins & Growth Rates

Integral Diagnostics's last 12 month revenue growth is 20%

Integral Diagnostics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Integral Diagnostics's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Integral Diagnostics's rule of X is 70% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Integral Diagnostics and other 15K+ public comps

Integral Diagnostics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	20%	XXX	23%	XXX	XXX	XXX
EBITDA Margin	20%	XXX	9%	XXX	XXX	XXX
EBITDA Growth	29%	XXX	94%	XXX	XXX	XXX
Rule of 40	29%	XXX	29%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	70%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	86%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial